Current Drug Therapy in Chronic Heart Failure: the New Guidelines of the European Society of Cardiology (ESC).

Author: Dominik BERLINER ¹ ; Johann BAUERSACHS
Author Information

1. Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany. berliner.dominik@mh-hannover.de, bauersachs.johann@mh-hannover.de
Publication Type:Review
Keywords: Heart failure; Standards; Drug therapy; Angiotensin receptor-neprilysin inhibitor
MeSH: Aging; Cardiology*; Cardiovascular Diseases; Drug Therapy*; Heart Failure*; Heart*; Hospitalization; Humans; Mortality; Prognosis
From:Korean Circulation Journal 2017;47(5):543-554
CountryRepublic of Korea
Language:English
Abstract: Congestive heart failure (HF) is a morbidity that is increasing worldwide due to the aging population and improvement in (acute) care for patients with cardiovascular diseases. The prognosis for patients with HF is very poor without treatment. Furthermore, (repeated) hospitalizations for cardiac decompensation cause an increasing economic burden. Modern drugs and the consequent implementation of therapeutic recommendations have substantially improved the morbidity and mortality of HF patients. This paper provides an overview of the current pharmacological management of HF patients, based on the 2016 guidelines of the European Society of Cardiology (ESC).